~~<i id='A84640BA67'><strike id='A84640BA67'><tt id='A84640BA67'><pre id='A84640BA67'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：comprehensive 2025-09-28 22:07:12 Page View：39

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bubonic plague hit France in 1720. Officials dithered. Sound familiar?
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

U.S. death rates show how politics are affecting public health

DrewAngerer/GettyImagesInanidealworld,publichealthwouldbeindependentofpolitics.YetrecenteventsintheU

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

XenotransplantrecipientRichardSlayman,holdinghandswithhispartnerFaren,poseswithLeonardoRiella(left),